应对新生儿和儿童的抗菌药耐药性威胁:由世界卫生组织发起的首次儿科抗生素药物优化活动的成果。

IF 19.9 1区 医学 Q1 PEDIATRICS
Alasdair Bamford PhD , Tiziana Masini PhD , Phoebe Williams DPhil , Prof Mike Sharland MD , Valeria Gigante PhD , Devika Dixit MD , Hatim Sati MD , Benedikt Huttner MD , Yasir Bin Nisar PhD , Bernadette Cappello MPH , Wilson Were MD , Jennifer Cohn MD , Martina Penazzato PhD , PADO-antibiotics participants
{"title":"应对新生儿和儿童的抗菌药耐药性威胁:由世界卫生组织发起的首次儿科抗生素药物优化活动的成果。","authors":"Alasdair Bamford PhD ,&nbsp;Tiziana Masini PhD ,&nbsp;Phoebe Williams DPhil ,&nbsp;Prof Mike Sharland MD ,&nbsp;Valeria Gigante PhD ,&nbsp;Devika Dixit MD ,&nbsp;Hatim Sati MD ,&nbsp;Benedikt Huttner MD ,&nbsp;Yasir Bin Nisar PhD ,&nbsp;Bernadette Cappello MPH ,&nbsp;Wilson Were MD ,&nbsp;Jennifer Cohn MD ,&nbsp;Martina Penazzato PhD ,&nbsp;PADO-antibiotics participants","doi":"10.1016/S2352-4642(24)00048-8","DOIUrl":null,"url":null,"abstract":"<div><p>Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, and focusing finite resources on the most appropriate agents for development and paediatric optimisation is urgently needed. In November and December, 2022, following the successes of previous similar disease-focused exercises, WHO convened the first Paediatric Drug Optimisation (PADO) exercise for antibiotics, aiming to provide a shortlist of antibiotics to be prioritised for paediatric research and development, especially for use in regions with the highest burden of disease attributable to serious bacterial infection. A range of antibiotics with either existing license for children or in clinical development in adults but with little paediatric data were considered, and PADO priority and PADO watch lists were formulated. This Review provides the background and overview of the exercise processes and its outcomes as well as a concise review of the literature supporting decision making. Follow-up actions to implement the outcomes from the PADO for antibiotics process are also summarised. This Review highlights the major beneficial influence the collaborative PADO process can have, both for therapeutic drug class and disease-specific themes, in uniting efforts to ensure children have access to essential medicines across the world.</p></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":null,"pages":null},"PeriodicalIF":19.9000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics\",\"authors\":\"Alasdair Bamford PhD ,&nbsp;Tiziana Masini PhD ,&nbsp;Phoebe Williams DPhil ,&nbsp;Prof Mike Sharland MD ,&nbsp;Valeria Gigante PhD ,&nbsp;Devika Dixit MD ,&nbsp;Hatim Sati MD ,&nbsp;Benedikt Huttner MD ,&nbsp;Yasir Bin Nisar PhD ,&nbsp;Bernadette Cappello MPH ,&nbsp;Wilson Were MD ,&nbsp;Jennifer Cohn MD ,&nbsp;Martina Penazzato PhD ,&nbsp;PADO-antibiotics participants\",\"doi\":\"10.1016/S2352-4642(24)00048-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, and focusing finite resources on the most appropriate agents for development and paediatric optimisation is urgently needed. In November and December, 2022, following the successes of previous similar disease-focused exercises, WHO convened the first Paediatric Drug Optimisation (PADO) exercise for antibiotics, aiming to provide a shortlist of antibiotics to be prioritised for paediatric research and development, especially for use in regions with the highest burden of disease attributable to serious bacterial infection. A range of antibiotics with either existing license for children or in clinical development in adults but with little paediatric data were considered, and PADO priority and PADO watch lists were formulated. This Review provides the background and overview of the exercise processes and its outcomes as well as a concise review of the literature supporting decision making. Follow-up actions to implement the outcomes from the PADO for antibiotics process are also summarised. This Review highlights the major beneficial influence the collaborative PADO process can have, both for therapeutic drug class and disease-specific themes, in uniting efforts to ensure children have access to essential medicines across the world.</p></div>\",\"PeriodicalId\":54238,\"journal\":{\"name\":\"Lancet Child & Adolescent Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":19.9000,\"publicationDate\":\"2024-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Child & Adolescent Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352464224000488\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Child & Adolescent Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352464224000488","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

摘要

儿童和新生儿极易受到抗菌药耐药性的影响。用于新生儿、儿童和 19 岁以下青少年的抗菌药物的研发面临巨大障碍,迫切需要将有限的资源集中用于最合适的药物研发和儿科药物优化。2022 年 11 月和 12 月,继以往类似的以疾病为重点的活动取得成功之后,世卫组织召开了首次抗生素儿科药物优化(PADO)活动,旨在提供一份优先用于儿科研发的抗生素短名单,尤其是在严重细菌感染导致疾病负担最重的地区使用的抗生素。对一系列已获得儿童用药许可或正在进行成人临床开发但几乎没有儿科数据的抗生素进行了审议,并制定了 PADO 优先列表和 PADO 观察列表。本综述介绍了工作背景、工作流程概述及其成果,并对支持决策的文献进行了简明扼要的综述。此外,还总结了为落实抗生素 PADO 流程的成果而采取的后续行动。本综述强调了 PADO 协作过程在治疗药物类别和特定疾病主题方面可产生的重大有益影响,以共同努力确保全球儿童获得基本药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics

Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, and focusing finite resources on the most appropriate agents for development and paediatric optimisation is urgently needed. In November and December, 2022, following the successes of previous similar disease-focused exercises, WHO convened the first Paediatric Drug Optimisation (PADO) exercise for antibiotics, aiming to provide a shortlist of antibiotics to be prioritised for paediatric research and development, especially for use in regions with the highest burden of disease attributable to serious bacterial infection. A range of antibiotics with either existing license for children or in clinical development in adults but with little paediatric data were considered, and PADO priority and PADO watch lists were formulated. This Review provides the background and overview of the exercise processes and its outcomes as well as a concise review of the literature supporting decision making. Follow-up actions to implement the outcomes from the PADO for antibiotics process are also summarised. This Review highlights the major beneficial influence the collaborative PADO process can have, both for therapeutic drug class and disease-specific themes, in uniting efforts to ensure children have access to essential medicines across the world.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lancet Child & Adolescent Health
Lancet Child & Adolescent Health Psychology-Developmental and Educational Psychology
CiteScore
40.90
自引率
0.80%
发文量
381
期刊介绍: The Lancet Child & Adolescent Health, an independent journal with a global perspective and strong clinical focus, presents influential original research, authoritative reviews, and insightful opinion pieces to promote the health of children from fetal development through young adulthood. This journal invite submissions that will directly impact clinical practice or child health across the disciplines of general paediatrics, adolescent medicine, or child development, and across all paediatric subspecialties including (but not limited to) allergy and immunology, cardiology, critical care, endocrinology, fetal and neonatal medicine, gastroenterology, haematology, hepatology and nutrition, infectious diseases, neurology, oncology, psychiatry, respiratory medicine, and surgery. Content includes articles, reviews, viewpoints, clinical pictures, comments, and correspondence, along with series and commissions aimed at driving positive change in clinical practice and health policy in child and adolescent health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信